Amarin Corporation plc
Feb 22, 2017

Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2016 financial results and provide an operational update on Tuesday, February 28th, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day. 

Event details:
The conference call can be heard live on the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 877-407-8033 within the United States or 201-689-8033 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010 (inside the United States) or 919-882-2331 (outside the United States). A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers please use conference ID 10260.

To ask questions:
During the teleconference, following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. Participants in the live teleconference will be provided an opportunity to ask questions. Investors may also e-mail their questions to investor.relations@amarincorp.com. E-mail questions will be accepted until 4:00 p.m. ET on Monday, February 27th, 2017.

About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information about Amarin, visit www.amarincorp.com.

Availability of other information about Amarin
Investors and others should note that Amarin communicates with its investors and the public using its website (www.amarincorp.com), its investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that Amarin posts on these channels, including Amarin's investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from Amarin's website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act or under the Securities and Exchange Act of 1934, as amended.

Amarin contact information:

Gene Mack

Executive Director, Investor Relations

Amarin Corporation

In U.S.: +1 (908) 719-1315

investor.relations@amarincorp.com



Lee M. Stern

Trout Group    

In U.S.: +1 (646) 378-2992

lstern@troutgroup.com



Media Inquiries:



Kristie Kuhl

Finn Partners

In U.S.: +1 (212) 583-2791

Kristie.kuhl@finnpartners.com

Primary Logo

Source: Amarin Corporation plc

News Provided by Acquire Media